Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5475261 | PMC |
| http://dx.doi.org/10.1161/CIRCULATIONAHA.117.027773 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
In heart failure patients with reduced ejection fraction, Sacubitril/valsartan (S/V) increased proBNP T71 glycosylation, which is regulated negatively by hypoxia via miR-30a . Using a cohort of 73 HFrEF patients who were transitioned from standard HF medication to S/V, we found that the increase in proBNP T71 glycosylation after S/V was associated with a decrease in cardiac hypoxia. We further found that plasma levels of K709-acteylated HIF1α, HIF-regulated and HIF-independent biomarkers also evolved consistently with a decrease in hypoxia.
View Article and Find Full Text PDFAvailability of comparative real-world evidence research in Medicare patients: implications for Centers for Medicare and Medicaid Services drug price negotiations.
J Comp Eff Res
November 2023
Scientific Research & Strategy, Aetion Inc., New York, NY 10001, USA.
To evaluate the availability of published comparative real-world evidence (RWE) studies in Medicare patients for the ten drugs set to undergo Centers for Medicare and Medicaid Services (CMS) price negotiations in 2026. A scoping review was completed in MEDLINE/PubMed to evaluate the availability of comparative RWE investigations conducted among Medicare-eligible patient populations in the US for the following drugs: apixaban, rivaroxaban, sitagliptin, ibrutinib, empagliflozin, etanercept, dapagliflozin, sacubitril/valsartan, ustekinumab and insulin aspart. Of the 170 real-world comparative studies identified, 55 (32.
View Article and Find Full Text PDFSacubitril/valsartan in real-life European patients with heart failure and reduced ejection fraction: a systematic review and meta-analysis.
ESC Heart Fail
October 2021
Cardiovascular Disease Unit, IRCCS Ospedale Policlinico San Martino, IRCCS Italian Cardiology Network, Genoa, Italy.
Aims: We systematically reviewed the European real-world evidence (RWE) about sacubitril-valsartan for heart failure with reduced ejection fraction.
Methods And Results: Twenty-one articles, including 16 952 subjects, were identified until 31 October 2020. Taking as reference the PARADIGM-HF cohort, few baseline characteristics were presented in >80% of these studies, most often with high heterogeneity.
Scope of Sacubitril/Valsartan Eligibility After Heart Failure Hospitalization: Findings From the GWTG-HF Registry (Get With The Guidelines-Heart Failure).
Circulation
May 2017
From Duke Clinical Research Institute (K.S.P., S.J.L., M.A.G., A.F.H.) and Department of Medicine (K.S.P., A.F.H.), Duke University School of Medicine, Durham, NC; Stanford University School of Medicine, Palo Alto, CA (P.A.H.); Bluhm Cardiovascular Institute, Northwestern University, Chicago, IL (C.W.Y.); and Geffen School of Medicine at University of California at Los Angeles (G.C.F.).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!